Hybrid Isatin and Imatinib Analogues as Potential Antineoplastic Agents

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Cancer is driven by genetic mutations affecting protein tyrosine kinases (PTKs) and signaling pathways like PI3K/Akt/mTOR.
• Tyrosine kinase inhibitors (TKIs) have transformed cancer therapy by targeting specific kinases, such as Bcr-Abl1 in chronic myeloid leukemia (CML) and KIT/PDGFRα in gastrointestinal stromal tumors (GISTs).

Purpose of the Study:

• To design, synthesize, and evaluate novel hybrid derivatives based on the isatin-phenylaminopyrimidine pyridine (PAPP) scaffold.
• To assess the cytotoxic activity of these derivatives against cancer cell lines with dysregulated tyrosine kinase activity.

Main Methods:

• Synthesis of 15 hybrid derivatives (4a-e, 5a-e, 6a-e) utilizing the PAPP scaffold.
• Evaluation of cytotoxicity using various cancer cell lines, including K562 (CML), DU145 (prostate), MCF7 (breast), HT29 (colon), NCI-H1299 (lung), and T98G (glioblastoma).
• Determination of half-maximal cytotoxic concentration (CC₅₀) values and assessment of erythrocytic toxicity.

Main Results:

• Compounds 6b and 6e demonstrated cytotoxicity against K562 cells (Bcr-Abl1 positive) with CC₅₀ values of 8.7 and 12.2 μM, respectively.
• Compound 4c exhibited strong cytotoxic activity against solid tumor cell lines, with CC₅₀ values ranging from 3.5 μM (MCF7) to 19.5 μM (NCI-H1299).
• All tested compounds displayed low toxicity to red blood cells (CC₅₀ > 30 μM).

Conclusions:

• The novel PAPP-based hybrid derivatives show potential as anticancer agents.
• Compound 4c is a promising candidate for targeting solid tumors, while compounds 6b and 6e warrant further investigation for CML treatment.
• The observed low erythrocytic toxicity suggests a favorable safety profile for these compounds.